Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab + DMARDs in RA
NCT01211834Phase 3Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Oct 2009
- Primary completion
- Oct 2010
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by JW Pharmaceutical Corporation. Started Oct 2009; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01211834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01211834.